Navigation Links
Bronchitol Cystic Fibrosis Dose Trial Results Positive
Date:8/11/2008

Bronchitol Demonstrates Dose-Related Improvements in Lung Function of

Cystic Fibrosis Patients

SYDNEY, Australia, Aug. 11 /Xinhua-PRNewswire-FirstCall/ -- Speciality pharmaceutical company Pharmaxis (ASX: PXS; Nasdaq: PXSL) today announced results from its Phase II trial, DPM-CF-202, in subjects with cystic fibrosis.

The trial achieved its primary end point of demonstrating a dose dependent improvement in lung function as measured by FVC (forced vital capacity) and FEV1 (the amount of air that can be forcibly exhaled in 1 second). At the end of the two-week Bronchitol treatment periods, changes in lung function were as follows:

-- 400 mg treatment group: FEV1 increased by 8.6%

(139 mls, p=0.0006 vs 40 mg)

-- 240 mg treatment group: FEV1 increased by 4.6% (87 mls)

-- 120 mg treatment group: FEV1 increased by 3.7% (42 mls)

-- 40 mg treatment group: FEV1 decreased by -1.6% (-33 mls)

FVC changed by +7.9% on 400 mg (p=0.0004 vs 40 mg), +3.9% on 240 mg, +1.5% on 120 mg and -0.6% on 40 mg.

Pharmaxis Chief Executive Officer Alan Robertson said, "The excellent result from this trial reaffirms that the 400 mg Bronchitol dose being used in the Phase 3 trials is optimal for its clinical effectiveness. We look forward to the results from the ongoing Phase 3 studies and to bringing Bronchitol to the market as rapidly as possible."

The study was an open, randomised comparison of 400mg, 240 mg, 120 mg and 40 mg of Bronchitol in 48 patients with cystic fibrosis at 12 centres across Canada and Argentina. Bronchitol was administered twice a day for 14 days in a crossover design.

Secondary endpoints of the study included other spirometry and quality of life measures. These measures also showed a positive effect for 400 mg Bronchitol on MMEF (maximum mid expiratory flow) and the respiratory domain of the cystic fibrosis quality of life questionnaire (CFQR).

Add
'/>"/>

SOURCE Pharmaxis Ltd
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Pharmaxis Long-Term Safety Study of Bronchitol Completes
2. Pharmaxis Establishes Named Patient Program for Bronchitol
3. Pharmaxis Concludes Special Protocol Assessment with FDA for Bronchitol Phase 3 Trial
4. Promising Cystic Fibrosis Compound on Track for Development
5. Symbollon Pharmaceuticals, Inc. Evaluates the Clinical Effects of IoGen(TM) on Fibrocystic Breast Disease
6. Pediatric Pulmonary Expert Comments on Study of Lung Transplants for Cystic Fibrosis
7. Cystic Fibrosis Foundation Reports Upward Trend for Key Health Outcomes
8. Cystic Fibrosis Foundation Announces Positive Early Results for Phase 2 Clinical Trial of VX-770 - an Oral Compound to Treat CF
9. Lung Transplants in Cystic Fibrosis Patients With Life-Threatening Bacteria Sparks Debate at ISHLT Meeting
10. PTC Therapeutics Announces Data Supporting Cough Frequency as a New Outcome Measure in Evaluating Treatments for Cystic Fibrosis
11. PTC Therapeutics Announces Data from Additional Clinical Studies of PTC124 in Cystic Fibrosis Confirming Activity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/7/2009)...and, January 7 Circassia Ltd, a sp...rgy and critical care, today,announced that follo...with,its ToleroMune(R) anti-allergy technology, t...for a further phase II clinical trial in cat aller...ecruited 120 patients with confirmed,cat allergie...
(Date:1/6/2009)... The Michael J. Fox Fou...our industry research teams for pre-clinical resea...sease. , , The funding was awarded under the Fo...This program, first launched in 2006, supports and...research. TDI is part of MJFF,s focus on ,de-r...
(Date:1/6/2009)...e, January 6 , - ...boration Until,December 2011 , - Expansion...body,Discovery in Ophthalmology , - Revise...rgan,Sublicenses to a Third Party , Exon...d a reinforcement,of its existing drug discovery ...
(Date:1/3/2009)... , , ROSEMONT, Ill., Jan. 2 /PRNewswire-USN...growing technology providing an increasing number ...f back pain according to an article in the January... of Orthopaedic Surgeons ( http://www.jaaos.org/ )...s, additional technical developments will allow MR...
Breaking Medicine Technology:Circassia Completes Patient Recruitment for Phase II Clinical Trial of Toleromune(R) Allergy Treatment 2Circassia Completes Patient Recruitment for Phase II Clinical Trial of Toleromune(R) Allergy Treatment 3Michael J. Fox Foundation Awards $2.7 Million to Four Industry Teams for Pre-Clinical Parkinson's Disease Research 2ExonHit Therapeutics Expands Strategic Collaboration With Allergan 2ExonHit Therapeutics Expands Strategic Collaboration With Allergan 3ExonHit Therapeutics Expands Strategic Collaboration With Allergan 4MRI Emerges As Vital Resource in Treatment of Back Pain 2MRI Emerges As Vital Resource in Treatment of Back Pain 3Roche completes acquisition of ARIUS 7890 1Roche completes acquisition of ARIUS 7890 2Connecticut State Medical Society and Genomas Co Sponsor Forum on DNA Guided Medicine and the Path to Personalized Health Care 7888 1Connecticut State Medical Society and Genomas Co Sponsor Forum on DNA Guided Medicine and the Path to Personalized Health Care 7888 2Experts Assert That Varian Technologies Deliver Speed and Clinical Accuracy in Treating Cancer Patients 3139 1Experts Assert That Varian Technologies Deliver Speed and Clinical Accuracy in Treating Cancer Patients 3139 2Experts Assert That Varian Technologies Deliver Speed and Clinical Accuracy in Treating Cancer Patients 3139 3Experts Assert That Varian Technologies Deliver Speed and Clinical Accuracy in Treating Cancer Patients 3139 4World Alzheimer 26apos 3Bs Day 2008 Special Report 3A New Alzheimer Targets Take Center Stage 26688 1World Alzheimer 26apos 3Bs Day 2008 Special Report 3A New Alzheimer Targets Take Center Stage 26688 2
... - Journal Article Also Demonstrates the Promise o...ibiotics -, PALO ALTO, Calif., June 21, 2007 /PRNe...d pharmaceutical company, announced,today that the...that details how AN2690, the company,s lead clinic...th synthesis of a specific,protein required for fu...
... FORT LEE, N.J.--(BUSINESS WIRE)--Jun 21, 2007 - N...ublication in the June 23 issue,of the journal The...ne therapy trial for Parkinson,s disease and the f...,s own brain cells for any adult,neurodegenerative... in 12 patients with,advanced Parkinson,s disease ...
Other Medicine Technology:Anacor Identifies a Novel Mechanism for Its Lead Anti-Fungal Drug,AN2690; Findings Published in Science 2Anacor Identifies a Novel Mechanism for Its Lead Anti-Fungal Drug,AN2690; Findings Published in Science 3Neurologix Announces Publication of Landmark Gene Therapy Study,Demonstrating Safety and Statistically Significant Improvement in,Patients With Advanced Parkinson's Disease 2Neurologix Announces Publication of Landmark Gene Therapy Study,Demonstrating Safety and Statistically Significant Improvement in,Patients With Advanced Parkinson's Disease 3Neurologix Announces Publication of Landmark Gene Therapy Study,Demonstrating Safety and Statistically Significant Improvement in,Patients With Advanced Parkinson's Disease 4Neurologix Announces Publication of Landmark Gene Therapy Study,Demonstrating Safety and Statistically Significant Improvement in,Patients With Advanced Parkinson's Disease 5Neurologix Announces Publication of Landmark Gene Therapy Study,Demonstrating Safety and Statistically Significant Improvement in,Patients With Advanced Parkinson's Disease 6
(Date:1/8/2009)...s are available that work, CDC officials stress ,...he most common strain of flu this season is resist...ernment health officials said Thursday there is no...n so far has been slow, and that other drugs work ... officials adopting a watchful attitude for now. ,...
(Date:1/8/2009)...May Be Revealed Friday, January 9 , , WASHINGT...ice Employees International Union (SEIU) President... International Executive Board to discuss the forc...mbers out of SEIU United Healthcare Workers-West (... final decision until tomorrow. , , According t...
(Date:1/8/2009)...ude study could shape new treatments for secondary...re-USNewswire/ -- Scientists at St. Jude Children,...tive treatment for bacterial pneumonia following i...cin and azithromycin, which kill bacteria by inhib...than a standard first-line treatment with the "bet...
(Date:1/8/2009)...Jude Children,s Research Hospital have demonstrate...ia following influenza. They found that the antibi...teria by inhibiting their protein synthesis, are m... with the "beta-lactam" antibiotic ampicillin, whi...e finding is important because pneumonia, rather t...
Breaking Medicine News(10 mins):Health News:Common Flu Strain Resistant to Popular Antiviral Drug 2Health News:Common Flu Strain Resistant to Popular Antiviral Drug 3Health News:SEIU Decision to Force Transfer of Long-Term Care Members Out of United Healthcare Workers Delayed 2Health News:Study Finds More Effective Treatment for Pneumonia Following Influenza 2Health News:Study Finds More Effective Treatment for Pneumonia Following Influenza 3Health News:Study finds more effective treatment for pneumonia following influenza 2Health News:Study finds more effective treatment for pneumonia following influenza 3
...sk of having a premature baby is up for women who ... cervix to eliminate precancerous cells, called LE...University revealed. After conducting a study in...hat nearly 1,500 premature births could have been ...
...ood - quick, convenient and cheap, which, we all k...ble cheeseburger costs less than a head of lettuce...es are one of the keys to good health; Barbara Rol...t encouraging people to eat large quantities of lo...
...rt published by the U.S. Centers for Disease Contr...is becoming widespread and aggressive among teenag...on pattern of excessive alcohol use" and the Natio...olism defines binge drinking as a pattern of drink...
...chers, in the first study of its kind, have comput...d found they are less prone to harm than collegiat...rs at Rhode Island Hospital and Brown Medical Scho...ished in the January 2007 issue of the American Jo...
Other Medicine News:Health News:Surfing Safer Than Soccer: Study 2Health News:Surfing Safer Than Soccer: Study 3
...l reference laboratory and a worldwide leader in i...P offers an extensive test menu of highly complex ...pathology. Owned by the University of Utah, ARUP L... nation's university teaching hospitals and childr...
...l reference laboratory and a worldwide leader in i...P offers an extensive test menu of highly complex ...pathology. Owned by the University of Utah, ARUP L... nation's university teaching hospitals and childr...
...l reference laboratory and a worldwide leader in i...P offers an extensive test menu of highly complex ...pathology. Owned by the University of Utah, ARUP L... nation's university teaching hospitals and childr...
...l reference laboratory and a worldwide leader in i...P offers an extensive test menu of highly complex ...pathology. Owned by the University of Utah, ARUP L... nation's university teaching hospitals and childr...
Medicine Products: